Gut Bacteria as Cause or Consequence in Inflammatory Bowel Disease

When a flare strikes, it can feel like the gut has turned against you. Alongside this, many people with inflammatory bowel disease (IBD) notice changes in their bowel habits and digestive comfort. What is harder to see is the microscopic shift happening simultaneously: changes in the trillions of bacteria that live in the gut. Whether these bacterial changes are a cause of IBD or a consequence of inflammation remains one of the most debated questions in gastroenterology.

What is gut bacteria?

The term gut bacteria refers to the microorganisms that live in the intestine, collectively known as the gut microbiota. These bacteria perform essential functions including breaking down food, producing vitamins, training the immune system, and protecting against harmful pathogens. In a healthy gut, hundreds of bacterial species coexist in balance, sometimes called eubiosis. When this balance is disrupted, resulting in a shift towards potentially harmful bacteria or loss of beneficial species, the state is referred to as dysbiosis.

The state of the microbiota in IBD

People with Crohn’s disease and ulcerative colitis consistently show different bacterial patterns compared to those without IBD. Studies report reduced diversity, meaning fewer species are present. Certain beneficial bacteria, particularly those from groups such as Faecalibacterium and Roseburia, which produce short-chain fatty acids (SCFAs) like butyrate, are often depleted. Simultaneously, there can be an increase in bacteria associated with inflammation, such as certain strains of Escherichia coli and members of the Proteobacteria group. These changes are seen in both active disease and, to a lesser extent, during remission.

Does dysbiosis cause IBD?

The question of causation is complex. Dysbiosis alone does not appear to cause IBD in people without genetic susceptibility. IBD arises from an interaction between genes, the immune system, environmental factors, and the microbiota. Some bacterial changes may precede the onset of IBD. For example, a loss of barrier-protective bacteria could allow other microbes to interact more closely with the gut lining, triggering an inappropriate immune response in someone genetically predisposed. However, it is difficult to determine whether these bacterial shifts are the spark or simply part of the environment that allows inflammation to begin.

Does inflammation change the microbiota?

What is clearer is that inflammation itself reshapes the bacterial community. When the gut lining is inflamed, oxygen levels increase in the intestinal lumen. Many beneficial bacteria are anaerobes, meaning they thrive in low-oxygen environments. As oxygen rises, these bacteria struggle, and oxygen-tolerant species, some of which are pro-inflammatory, take their place. Inflammation also increases the availability of certain nutrients, such as nitrate and sulphate, which favour the growth of specific bacterial groups. Antimicrobial peptides released by the immune system further alter the microbial landscape. In this way, inflammation actively selects for a different community.

The feedback loop

Rather than a simple cause or consequence, the relationship is likely bidirectional. Dysbiosis may contribute to immune activation, and inflammation then worsens dysbiosis, creating a self-reinforcing cycle. The immune system in IBD may respond excessively to bacteria that would normally be tolerated, whilst the altered bacterial community may produce metabolites or signals that perpetuate immune activation. This feedback loop makes it difficult to separate initiating factors from maintaining factors. Breaking the cycle, either by calming inflammation or supporting microbial recovery, remains a central challenge in IBD management.

Short-chain fatty acids and the gut lining

One of the most important products of gut bacteria is butyrate, a short-chain fatty acid produced when bacteria ferment dietary fibre. Butyrate is the primary fuel for colonocytes, the cells lining the colon, and plays a role in maintaining the gut barrier and regulating immune responses. In IBD, butyrate-producing bacteria are often reduced, and this may contribute to barrier dysfunction and inflammation. The loss of butyrate production is both a marker of dysbiosis and a potential contributor to disease persistence.

Dietary influence on the microbiota

Diet is one of the most modifiable factors affecting the gut microbiota. Diets high in fibre, particularly from diverse plant sources, support a wide range of bacterial species and promote SCFA production. Conversely, diets high in processed foods, emulsifiers, and certain additives may reduce microbial diversity and favour inflammatory species. In IBD, dietary tolerance varies, and some people find that certain fibres trigger symptoms during active inflammation. This does not mean fibre is harmful, but rather that the gut’s capacity to tolerate it fluctuates. Working with a dietitian to identify tolerated sources and reintroduce variety during remission can support microbial recovery without provoking symptoms.

Antibiotics and microbial disruption

Antibiotics are sometimes used in IBD, particularly in Crohn’s disease with perianal involvement or in pouchitis. Whilst they can reduce bacterial overgrowth or target specific pathogens, they also disrupt the broader microbial community, often reducing diversity. Repeated courses can lead to more pronounced dysbiosis. This does not mean antibiotics should be avoided when clinically indicated, but their impact on the microbiota is an important consideration.

Probiotics, prebiotics, and faecal microbiota transplantation

There is considerable interest in using probiotics, prebiotics, or faecal microbiota transplantation (FMT) to restore a healthier bacterial community. Evidence is mixed. Some probiotic strains, particularly VSL#3 (now marketed as Visbiome in some regions), have shown benefit in pouchitis. However, results in Crohn’s disease and ulcerative colitis are inconsistent, and not all strains are equally effective. Prebiotics, which are fibres that feed beneficial bacteria, may support SCFA production but must be introduced carefully. FMT has shown promise in ulcerative colitis in some trials, but responses vary and long-term safety and efficacy remain under investigation. These approaches are not yet standard treatment but represent an evolving area of research.

Practical takeaways

• Understand that changes in gut bacteria are common in IBD and reflect both the disease and the effects of inflammation.
• Work with a dietitian to identify tolerated sources of fibre and gradually increase variety during periods of remission.
• Avoid unnecessary antibiotic use where possible, but do not withhold antibiotics when they are medically indicated.
• If considering probiotics, discuss specific strains and evidence with your healthcare team, as not all products are equivalent.
• Recognise that restoring microbial balance is a long-term process and unlikely to happen quickly or with a single intervention.

Conclusion

The relationship between gut bacteria and IBD is neither purely causal nor purely reactive. Dysbiosis and inflammation interact in a cycle that sustains disease and complicates recovery. Whilst we cannot yet fully restore a healthy microbiota through intervention alone, understanding this relationship helps explain why diet, antibiotics, and other environmental factors matter. Managing IBD effectively involves addressing inflammation with medical treatment whilst supporting the conditions that allow a more balanced microbial community to recover over time.

References

1. Nishida A, Inoue R, Inatomi O, et al. Gut microbiota in the pathogenesis of inflammatory bowel disease. Clin J Gastroenterol. 2018;11(1):1-10. doi:10.1007/s12328-017-0813-5

1. Pascal V, Pozuelo M, Borruel N, et al. A microbial signature for Crohn’s disease. Gut. 2017;66(5):813-822. doi:10.1136/gutjnl-2016-313235

1. Lloyd-Price J, Arze C, Ananthakrishnan AN, et al. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 2019;569(7758):655-662. doi:10.1038/s41586-019-1237-9

1. Sokol H, Pigneur B, Watterlot L, et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105(43):16731-16736. doi:10.1073/pnas.0804812105

1. Machiels K, Joossens M, Sabino J, et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63(8):1275-1283. doi:10.1136/gutjnl-2013-304833

1. Hughes ER, Winter MG, Duerkop BA, et al. Microbial respiration and formate oxidation as metabolic signatures of inflammation-associated dysbiosis. Cell Host Microbe. 2017;21(2):208-219. doi:10.1016/j.chom.2017.01.005

1. Turpin W, Espin-Garcia O, Xu W, et al. Association of host genome with intestinal microbial composition in a large healthy cohort. Nat Genet. 2016;48(11):1413-1417. doi:10.1038/ng.3693

1. Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet. 2017;389(10075):1218-1228. doi:10.1016/S0140-6736(17)30182-4

This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional medical guidance, diagnosis, or treatment.

More from Gastro Living